686 related articles for article (PubMed ID: 16520744)
1. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.
Fredj S; Sampson KJ; Liu H; Kass RS
Br J Pharmacol; 2006 May; 148(1):16-24. PubMed ID: 16520744
[TBL] [Abstract][Full Text] [Related]
2. Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?
Makielski JC; Valdivia CR
Br J Pharmacol; 2006 May; 148(1):4-6. PubMed ID: 16520741
[TBL] [Abstract][Full Text] [Related]
3. State- and use-dependent block of muscle Nav1.4 and neuronal Nav1.7 voltage-gated Na+ channel isoforms by ranolazine.
Wang GK; Calderon J; Wang SY
Mol Pharmacol; 2008 Mar; 73(3):940-8. PubMed ID: 18079277
[TBL] [Abstract][Full Text] [Related]
4. Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening.
Moreno JD; Yang PC; Bankston JR; Grandi E; Bers DM; Kass RS; Clancy CE
Circ Res; 2013 Sep; 113(7):e50-e61. PubMed ID: 23897695
[TBL] [Abstract][Full Text] [Related]
5. Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel Na(v)1.5: a novel mechanism of drug action.
Beyder A; Strege PR; Reyes S; Bernard CE; Terzic A; Makielski J; Ackerman MJ; Farrugia G
Circulation; 2012 Jun; 125(22):2698-706. PubMed ID: 22565935
[TBL] [Abstract][Full Text] [Related]
6. Is ranolazine an antiarrhythmic drug?
Eckhardt LL; Teelin TC; January CT
Am J Physiol Heart Circ Physiol; 2008 May; 294(5):H1989-91. PubMed ID: 18375723
[No Abstract] [Full Text] [Related]
7. Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.
Du C; Zhang Y; El Harchi A; Dempsey CE; Hancox JC
J Mol Cell Cardiol; 2014 Sep; 74(100):220-30. PubMed ID: 24877995
[TBL] [Abstract][Full Text] [Related]
8. Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability.
Estacion M; Waxman SG; Dib-Hajj SD
Mol Pain; 2010 Jun; 6():35. PubMed ID: 20529343
[TBL] [Abstract][Full Text] [Related]
9. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.
Burashnikov A; Di Diego JM; Zygmunt AC; Belardinelli L; Antzelevitch C
Circulation; 2007 Sep; 116(13):1449-57. PubMed ID: 17785620
[TBL] [Abstract][Full Text] [Related]
10. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current.
Undrovinas AI; Belardinelli L; Undrovinas NA; Sabbah HN
J Cardiovasc Electrophysiol; 2006 May; 17 Suppl 1(Suppl 1):S169-S177. PubMed ID: 16686675
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: II. Insights from a mathematical model.
Nesterenko VV; Zygmunt AC; Rajamani S; Belardinelli L; Antzelevitch C
Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1615-24. PubMed ID: 21821780
[TBL] [Abstract][Full Text] [Related]
12. Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome.
Abriel H; Wehrens XH; Benhorin J; Kerem B; Kass RS
Circulation; 2000 Aug; 102(8):921-5. PubMed ID: 10952963
[TBL] [Abstract][Full Text] [Related]
13. Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine.
Sicouri S; Timothy KW; Zygmunt AC; Glass A; Goodrow RJ; Belardinelli L; Antzelevitch C
Heart Rhythm; 2007 May; 4(5):638-47. PubMed ID: 17467634
[TBL] [Abstract][Full Text] [Related]
14. Y1767C, a novel SCN5A mutation, induces a persistent Na+ current and potentiates ranolazine inhibition of Nav1.5 channels.
Huang H; Priori SG; Napolitano C; O'Leary ME; Chahine M
Am J Physiol Heart Circ Physiol; 2011 Jan; 300(1):H288-99. PubMed ID: 21076026
[TBL] [Abstract][Full Text] [Related]
15. An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes.
Song Y; Shryock JC; Belardinelli L
Am J Physiol Heart Circ Physiol; 2008 May; 294(5):H2031-9. PubMed ID: 18310511
[TBL] [Abstract][Full Text] [Related]
16. Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide.
Nagatomo T; January CT; Makielski JC
Mol Pharmacol; 2000 Jan; 57(1):101-7. PubMed ID: 10617684
[TBL] [Abstract][Full Text] [Related]
17. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome.
Wu L; Shryock JC; Song Y; Li Y; Antzelevitch C; Belardinelli L
J Pharmacol Exp Ther; 2004 Aug; 310(2):599-605. PubMed ID: 15031300
[TBL] [Abstract][Full Text] [Related]
18. Ranolazine inhibits shear sensitivity of endogenous Na+ current and spontaneous action potentials in HL-1 cells.
Strege P; Beyder A; Bernard C; Crespo-Diaz R; Behfar A; Terzic A; Ackerman M; Farrugia G
Channels (Austin); 2012; 6(6):457-62. PubMed ID: 23018927
[TBL] [Abstract][Full Text] [Related]
19. Eleclazine exhibits enhanced selectivity for long QT syndrome type 3-associated late Na
El-Bizri N; Xie C; Liu L; Limberis J; Krause M; Hirakawa R; Nguyen S; Tabuena DR; Belardinelli L; Kahlig KM
Heart Rhythm; 2018 Feb; 15(2):277-286. PubMed ID: 29017927
[TBL] [Abstract][Full Text] [Related]
20. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties.
Antzelevitch C; Belardinelli L; Zygmunt AC; Burashnikov A; Di Diego JM; Fish JM; Cordeiro JM; Thomas G
Circulation; 2004 Aug; 110(8):904-10. PubMed ID: 15302796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
